| Autor: |
Daniel J.L. Coleman, Peter Keane, Paulynn S. Chin, Luke Ames, Sophie Kellaway, Helen Blair, Naeem Khan, James Griffin, Elizabeth Holmes, Alexander Maytum, Sandeep Potluri, Lara Strate, Kinga Koscielniak, Manoj Raghavan, John Bushweller, Olaf Heidenreich, Terry Rabbitts, Peter N. Cockerill, Constanze Bonifer |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
iScience, Vol 27, Iss 4, Pp 109576- (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2589-0042 |
| DOI: |
10.1016/j.isci.2024.109576 |
| Popis: |
Summary: AML is characterized by mutations in genes associated with growth regulation such as internal tandem duplications (ITD) in the receptor kinase FLT3. Inhibitors targeting FLT3 (FLT3i) are being used to treat patients with FLT3-ITD+ but most relapse and become resistant. To elucidate the resistance mechanism, we compared the gene regulatory networks (GRNs) of leukemic cells from patients before and after relapse, which revealed that the GRNs of drug-responsive patients were altered by rewiring their AP-1-RUNX1 axis. Moreover, FLT3i induces the upregulation of signaling genes, and we show that multiple cytokines, including interleukin-3 (IL-3), can overcome FLT3 inhibition and send cells back into cycle. FLT3i leads to loss of AP-1 and RUNX1 chromatin binding, which is counteracted by IL-3. However, cytokine-mediated drug resistance can be overcome by a pan-RAS inhibitor. We show that cytokines instruct AML growth via the transcriptional regulators AP-1 and RUNX1 and that pan-RAS drugs bypass this barrier. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
